Response to Imatinib in e13a2 Versus e14a2 BCR-ABL Fusion Transcripts in Chronic Myeloid Leukemia Saudi Patients

被引：1

作者：

Elbjeirami, Wafa M. ^{[1
]}

Alabdulwahab, Amal S. ^{[2
]}

Elsayed, Hussein G. ^{[2
]}

Abdelghaffer, Nermeen Adel ^{[2
,3
]}

Elnagdi, Noha ^{[4
,5
]}

Al-Jedani, Hanadi ^{[4
]}

Abd Allatif, Nahla ^{[4
,5
]}

Al Shaikh, Abdulaziz ^{[4
]}

Al-Allaf, Faisal ^{[1
]}

机构：

[1] Mol Diagnost Sect, Dept Lab & Blood Bank, King, WI, Saudi Arabia

[2] Dept Hematol, King, WI, Saudi Arabia

[3] Ain Shams Univ, Dept Hematol, Cairo, Egypt

[4] Hematol Sect, Dept Lab & Blood Bank, King, WI, Saudi Arabia

[5] Natl Canc Inst Cairo Univ, Dept Clin Pathol, Cairo, Egypt

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.5453.5453

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5453

引用

页数：5

共 50 条

[31] DETECTION OF AN ABERRANT FORM OF E13A2 BCR-ABL TRANSCRIPT CAUSING FAILURE OF MOLECULAR DIAGNOSTICS IN PATIENT WITH CHRONIC MYELOID LEUKEMIA (CML) [J].

Jurcek, T. ;

Razga, F. ;

Jeziskova, I. ;

Zackova, D. ;

Mayer, J. ;

Dvorakova, D. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 :676-676

[32] Molecular breakpoint of BCR-ABL in chronic myeloid leukemia and imatinib response [J].

不详 .

PHARMACOGENOMICS, 2010, 11 (09) :1202-1203

[33] Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib. [J].

Cayuela, JM ;

Rousselot, P ;

Nicolini, F ;

Espinouse, D ;

Ollagnier, C ;

Bui-Thi, MH ;

Chabane, K ;

Raffoux, E ;

Tigaud, I ;

Magaud, JP ;

Hayette, S .

BLOOD, 2005, 106 (11) :287B-287B

[34] Chronic myeloid leukaemia patients with the e14a2 BCR-ABL transcript type have a distinct phenotype with a trend to improved major molecular response rates [J].

Chauhan, S. ;

Barkhuizen, A. ;

MacWhannell, A. ;

Jacob, A. ;

Lee, S. ;

Basu, S. ;

Francis, S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 :133-133

[35] Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia [J].

Langabeer, Stephen E. ;

Crampe, Mireille ;

Haslam, Karl ;

Kelly, Johanna ;

Cahill, Mary R. .

LEUKEMIA RESEARCH, 2010, 34 (07) :E176-E177

[36] Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: Benign course responsive to imatinib with an RT-PCR advisory [J].

Snyder, DS ;

McMahon, R ;

Cohen, SR ;

Slovak, ML .

AMERICAN JOURNAL OF HEMATOLOGY, 2004, 75 (02) :92-95

[37] Assessment of BCR-ABL1 Fusion Transcripts and Their Association with Response to Imatinib Treatment in Chronic Myeloid Leukemia Patients [J].

Kagita, Sailaja ;

Mamidi, Tulasi Krishna ;

Digumarti, Leela ;

Gundeti, Sadasivudu ;

Digumarti, Raghunadharao .

INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2018, 39 (02) :165-171

[38] Response to Imatinib Treatment in Chronic Myeloid Leukemia According to BCR-ABL Transcript [J].

Acosta Hernandez, Titania del Carmen ;

Best Aguilera, Carlos Roberto ;

Villela Martinez, Luis Mario ;

Guzman Hernandez, Alicia Elizabeth ;

Robles Rodriguez, Arianna ;

Lopez Hernandez, Juan Carlos ;

Gomez Vazquez, Oscar Rodrigo ;

Rivera Mendoza, Laura Adriana ;

Garcia Reyes, Barbara ;

Gutierrez Alatorre, Aldo Fernando Adrian ;

Calderon Valdez, Areli Sarai ;

Visuetti Pimentel, Saribethe Mahely .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 :S242-S243

[39] First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts [J].

Andrikovics, Hajnalka ;

Nahajevszky, Sarolta ;

Szilvasi, Aniko ;

Bors, Andras ;

Adam, Emma ;

Kozma, Andras ;

Kajtar, Bela ;

Barta, Aniko ;

Poros, Anna ;

Tordai, Attila .

HEMATOLOGICAL ONCOLOGY, 2007, 25 (03) :143-147

[40] Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript [J].

A Tchirkov ;

J-L Couderc ;

B Périssel ;

C Goumy ;

A Regnier ;

N Uhrhammer ;

P Verrelle ;

M Berger .

Leukemia, 2006, 20 :167-168

← 1 2 3 4 5 →